Baillie Gifford & Co
ABCL icon

Baillie Gifford & Co’s AbCellera Biologics ABCL Stock Holding History

Baillie Gifford & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,422,966
Closed -$52.4M – 267
2025
Q3 		$52.4M Buy
10,422,966
+62,962
+0.6% +$277K 0.04% 147
2025
Q2 		$35.5M Sell
10,360,004
-835,828
-7% -$2.08M 0.03% 165
2025
Q1 		$25M Sell
11,195,832
-1,040,633
-9% -$2.98M 0.02% 171
2024
Q4 		$35.9M Sell
12,236,465
-658,238
-5% -$1.83M 0.03% 158
2024
Q3 		$33.5M Sell
12,894,703
-9,016,311
-41% -$25M 0.03% 161
2024
Q2 		$64.9M Sell
21,911,014
-1,269,075
-5% -$4.8M 0.05% 129
2024
Q1 		$105M Sell
23,180,089
-864,707
-4% -$4.41M 0.08% 122
2023
Q4 		$137M Sell
24,044,796
-2,159,853
-8% -$10M 0.11% 118
2023
Q3 		$121M Sell
26,204,649
-160,102
-0.6% -$974K 0.11% 114
2023
Q2 		$170M Buy
26,364,751
+6,535,100
+33% +$44.6M 0.14% 104
2023
Q1 		$150M Buy
19,829,651
+132,916
+0.7% +$1.21M 0.13% 105
2022
Q4 		$200M Buy
19,696,735
+6,339,067
+47% +$73.2M 0.21% 89
2022
Q3 		$132M Buy
13,357,668
+2,953
+0% +$32.4K 0.14% 104
2022
Q2 		$142M Buy
13,354,715
+2,305,950
+21% +$19.5M 0.15% 106
2022
Q1 		$108M Buy
11,048,765
+7,474,857
+209% +$70.8M 0.08% 136
2021
Q4 		$51.1M Buy
3,573,908
+333,365
+10% +$5.06M 0.03% 185
2021
Q3 		$64.9M Buy
3,240,543
+515,346
+19% +$9.11M 0.03% 167
2021
Q2 		$60M Buy
2,725,197
+1,569,844
+136% +$43.3M 0.03% 177
2021
Q1 		$39.2M Buy
+1,155,353
New +$46M 0.02% 196

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co's ABCL Position: Q4 2025 in Review

Baillie Gifford & Co sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 10,422,966 shares — an estimated $52.4M sold.

Baillie Gifford & Co first reported a position in ABCL in Q1 2021 and held it in 19 quarters. The position peaked at $200M in Q4 2022. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Baillie Gifford & Co reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Baillie Gifford & Co sold 10,422,966 AbCellera Biologics shares in Q4 2025, an estimated $52.4M.
  • Baillie Gifford & Co first reported a position in AbCellera Biologics in Q1 2021 and held it in 19 quarters.
  • Baillie Gifford & Co's AbCellera Biologics position peaked at $200M in Q4 2022.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Baillie Gifford & Co's 13F filing for Q4 2025, filed 23 Jan 2026.